category,datetime,headline,id,image,related,source,summary,url
company,1769234957,Is Viatris (VTRS) Pricing Reflect Its Recent Multiâ€‘Year Share Price Recovery,138236382,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VTRS,Yahoo,"If you are wondering whether Viatris might still offer value at its current share price, this article walks through what the numbers are really saying about the stock. The shares recently closed at US$13.21, with returns of 2.7% over 7 days, 7.9% over 30 days, 6.0% year to date, 23.9% over 1 year and 27.5% over 3 years, while the 5 year return sits at a 4.9% decline. Recent news coverage has focused on Viatris as a large U.S. listed pharmaceuticals and biotech company. This keeps investor...",https://finnhub.io/api/news?id=64cc05007e6fd4c03552f123c22e8087b1b302cff4bacb6d04cacb5f04457a80
company,1769217040,Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch,138230677,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VTRS,Yahoo,"Viatris (VTRS) is back in focus after the company launched its heart failure treatment Inpefa in the United Arab Emirates, marking its first commercialization of the drug outside the U.S. and Europe. See our latest analysis for Viatris. The Inpefa launch lands at a time when momentum in Viatris' share price has been building, with a 30 day share price return of 7.92% and a 90 day share price return of 27.63%. The 1 year total shareholder return sits at 23.94%, compared with a weaker 5 year...",https://finnhub.io/api/news?id=bc7df214f3fb9658b929e5850df769b03743b6c2d32a0988d5060d1db414f666
